1. P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX-BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE. (23rd June 2022) Authors: Wolach, O.; Garcia, J. S.; Vachhani, P.; Zeidner, J.; Lai, C.; Moshe, Y.; Xavier, M.; Lee, S.; Zuckerman, T.; Pollyea, D. A.; Abedin, S.; Chen, E. C.; Bathini, S.; Edwards, W.; Bui, C. N.; Cheng, W. W.-H.; Svensson, A.; Guérin, A.; Maitland, J.; Ma, E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 418 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P540: PEVONEDISTAT, AZACITIDINE AND VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA– A PHASE I STUDY. (23rd June 2022) Authors: Guru Murthy, G. S.; Kaufmann, S.; Saliba, A.; Szabo, A.; Michaelis, L.; Abedin, S.; Runaas, L.; Carlson, K.; Maldonado-Schmidt, S.; Hinman, A.; Thomas, A.; Baim, A.; Litzow, M.; Atallah, E. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 439 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗